Managing Directors Vincent Walden, Rich Goode and Steve Spiegelhatler recently published an article for the Association of Certified Fraud Examiners (ACFE)'s Fraud Magazine titled “Place 'ESG' on Your Radar."

The complex pharmaceutical landscape in Europe — especially in Germany — make financial planning and forecasting a difficult and formidable process. To overcome such challenges, drug manufacturers and other companies in the industry are discovering that financial modeling in health care is crucial to predicting future revenue streams, annual budgets, and winning the drug tender game in socialized medicine.

NHSEI has published its new guidance on provider collaboratives setting out how trusts can work together effectively at scale to transform services, tackle unwarranted variation, and deliver the best care for patients and communities. Managing Director, Schellion Horn sets out some lesson learned and top tips for those looking to set up provider collaborative

HMRC continues to promote its Profit Diversion Compliance Facility (the “PDCF”), with all indicators continuing to point to the Facility being a mainstay in HMRC’s tax collection toolbox, particularly given the pressure on HMRC to cover the public costs of COVID-19.

Whether through a traditional IPO, SPAC acquisition, or direct listing, the transition from private to public company comes with an entirely new set of challenges, including increased regulatory oversight, novel corporate governance issues, and growing stakeholder demands for increased transparency and accountability.

The semiconductor chip shortage is expected to be felt into 2022 as the industry continues to work through production shutdowns and delays. Total vehicle inventory remains depressed and is constraining sales numbers as a result.

COVID-19 increased the demand for patient-centric supply chains, and approvals for high-value, small-patient population medicines are rising. Our experts explore the fundamental implications for pharma operations and its path to recovery.

Did you know that failed nondiscrimination tests can require costly corrections for plan sponsors? What are the implications of these 401(k) testing corrections on the company for the present and future? Learn more about how your plans should go about remediating 401(k) testing failures.

A&M advises governments on innovative ways to transform through strategic allocation of resources, management of federal funding and compliance requirement support.

CEO no Brasil da consultoria norte-americana fala sobre as principais necessidades de diferentes clientes para navegar melhor nos assuntos de ESG

Welcome to A&M’s UK Executive Compensation Services page, where you can view all recent reports, updates and events.

INSOL International, a leading global federation of insolvency and restructuring professionals, has appointed Alvarez & Marsal’s Tiffany Wong, Managing Director, Asia Restructuring and Insolvency Practice, to its Executive Committee as Treasurer.

Colin Harvey, Managing Director with Alvarez & Marsal’s Corporate Performance Improvement (CPI) practice and National Solution Leader for CPI’s Corporate M&A Services, was recently featured in the NACD BoardTalk blog discussing post-COVID mergers and acquisitions (M&A) activity and five areas that boards should focus on.